{"id":36333,"date":"2026-04-02T11:13:00","date_gmt":"2026-04-02T15:13:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36333"},"modified":"2026-03-08T14:25:11","modified_gmt":"2026-03-08T18:25:11","slug":"how-to-stop-a-90-revenue-crash-mapping-patent-thickets-to-survive-the-new-exclusivity-slope","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/how-to-stop-a-90-revenue-crash-mapping-patent-thickets-to-survive-the-new-exclusivity-slope\/","title":{"rendered":"How to stop a 90% revenue crash: Mapping patent thickets to survive the new exclusivity slope"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The Cliff Is Real, and the Numbers Are Getting Worse<\/h2>\n\n\n\n

The pharmaceutical revenue cliff is not a metaphor. It is a financial event that has wiped out billions of dollars in branded revenue within 18 months of generic entry, repeatedly and predictably, across virtually every therapeutic category. When Lipitor lost its exclusivity in November 2011, Pfizer’s revenues from the drug fell from roughly $5.9 billion in the United States alone to less than $1 billion within two years\u2014a collapse approaching 85% [1]. When Humira’s first biosimilar competitors reached US pharmacies in earnest in 2023, AbbVie’s US Humira revenues fell 36% in the first year\u2014and the trajectory continued downward [2]. These are not anomalies. They are the standard outcome when patent protection ends without an adequate defensive architecture in place.<\/p>\n\n\n\n

What has changed is the speed of the collapse and the sophistication of the attackers. Generic manufacturers and biosimilar developers now file their challenges earlier, pursue them more aggressively through the Patent Trial and Appeal Board (PTAB), and use AI-assisted prior art searches that can find vulnerabilities in patent claims that human searchers would have missed. The window between patent expiration and meaningful revenue destruction has compressed. The tools available to defend against it have multiplied, but so has the legal and strategic knowledge on the other side of the table.<\/p>\n\n\n\n

This article is a practical guide to understanding, mapping, and surviving the exclusivity slope. It covers the mechanics of patent thickets, how to build and audit one, where they fail, how competitors attack them, and what financial modeling you need to estimate your exposure. It draws on case studies from Lipitor to Humira to Seroquel, on data from regulatory databases and PTAB filings, and on the analytical frameworks that IP and business development professionals actually use.<\/p>\n\n\n\n

\n\n\n\n

What a Patent Thicket Actually Is<\/h2>\n\n\n\n

The term “patent thicket” entered pharmaceutical vocabulary from the technology sector, where it described a dense web of overlapping patents that any new entrant had to navigate. In pharma, the concept is structurally similar but the strategic goal differs. In tech, thickets often emerge organically from competing innovators. In pharma, they are typically constructed deliberately by the originator company to extend the commercial life of a drug beyond the expiration of its foundational composition-of-matter patent.<\/p>\n\n\n\n

A pharmaceutical patent thicket is a cluster of patents covering different aspects of the same drug or drug product. These aspects can include the active pharmaceutical ingredient (API) itself, specific crystalline forms or polymorphs, formulation characteristics, delivery mechanisms, dosing regimens, metabolites, combination products, and specific indications. Each patent has its own expiration date, and together they create a layered schedule of protection that outlasts any single claim.<\/p>\n\n\n\n

The legal basis for this strategy is straightforward. US patent law does not prohibit filing multiple patents on the same drug. The FDA’s Orange Book allows originators to list patents that cover the drug substance, drug product, and method of use. Generic applicants under the Abbreviated New Drug Application (ANDA) process must either design around each listed patent or challenge its validity. The more patents are listed, the more challenges a generic company must mount, the more expensive and time-consuming the litigation becomes, and the stronger the originator’s bargaining position.<\/p>\n\n\n\n

The Three Layers of Pharmaceutical IP Protection<\/h3>\n\n\n\n

A well-constructed pharmaceutical IP portfolio operates across three distinct layers. Understanding these layers is the starting point for both building a thicket and analyzing competitors’ vulnerabilities.<\/p>\n\n\n\n

Compound Patents<\/h4>\n\n\n\n

The compound patent, also called the composition-of-matter patent, covers the active molecule itself. It is typically the first patent filed and the one that expires earliest. It provides the strongest protection because it covers the molecule regardless of formulation, indication, or dosing. Once it expires, generic manufacturers can synthesize and market the API. This is the “primary” cliff. It is also the most predictable one, since compound patents are usually filed early in clinical development and run 20 years from filing, subject to patent term extension (PTE).<\/p>\n\n\n\n

Compound patents are the hardest to challenge because they require demonstrating that the molecule was previously known or obvious before the patent filing date. They are also the hardest to extend, which is why the pharmaceutical industry has developed the other two layers.<\/p>\n\n\n\n

Formulation and Delivery Patents<\/h4>\n\n\n\n

The second layer covers the physical form of the drug product: the tablet, capsule, solution, or device that delivers the API. Formulation patents can cover specific polymorphic forms of the API (which may affect bioavailability, stability, or solubility), excipient combinations, modified-release mechanisms, controlled-release coatings, and the physical characteristics of the dosage form.<\/p>\n\n\n\n

These patents are often filed during Phase II or Phase III clinical development, when the preferred formulation is being finalized. They expire later than compound patents and are more vulnerable to validity challenges because formulation science is a well-documented field with substantial prior art. The standard of non-obviousness\u2014the key requirement for patentability\u2014is harder to meet when the general approach is well established and an experienced formulator might reasonably have arrived at the same solution.<\/p>\n\n\n\n

Method-of-Use Patents<\/h4>\n\n\n\n

The third layer covers how the drug is used: specific indications, dosing schedules, patient populations, and treatment protocols. Method-of-use patents are typically the last filed and the last to expire. They are also the most limited in scope, because a generic manufacturer can design around a method-of-use patent by not listing that specific indication on its label\u2014a practice called “carve-out” or “skinny labeling.”<\/p>\n\n\n\n

The interaction between method-of-use patents and skinny labeling has become one of the most contested areas of pharmaceutical patent law. GlaxoSmithKline vs. Teva, decided by the Federal Circuit in 2020, held that a generic manufacturer could be liable for induced infringement even when it used a skinny label, if its marketing communications pointed to the patented use [3]. The decision\u2014and its subsequent clarification on rehearing\u2014created uncertainty that has made method-of-use patents both more valuable and more difficult to deploy cleanly.<\/p>\n\n\n\n

Why Thickets Work (When They Do)<\/h3>\n\n\n\n

The mechanism by which a thicket extends commercial exclusivity is not simply the duration of any individual patent. It is the aggregate burden imposed on any generic challenger. Each patent listed in the Orange Book that a generic applicant certifies against under Paragraph IV triggers a potential 30-month stay of FDA approval. If the originator files suit within 45 days of receiving the Paragraph IV notice, the stay activates automatically and blocks FDA from approving the ANDA for 30 months or until a court decision, whichever comes first.<\/p>\n\n\n\n

A drug with eight Orange Book-listed patents represents eight potential certification challenges. Even if a generic company challenges all eight simultaneously in a single lawsuit, the litigation process takes years and carries significant uncertainty. The legal costs of an ANDA patent trial easily exceed $10 million per side. Small generic manufacturers may be deterred from challenging at all. Even well-capitalized generic firms must make strategic choices about which drugs to challenge and which to skip.<\/p>\n\n\n\n

The thicket works by raising the cost of entry to a level that deters some competitors, delays others, and creates opportunities for negotiated resolutions that preserve some originator revenue. It does not eliminate competition permanently. It buys time.<\/p>\n\n\n\n

\n\n\n\n

The Anatomy of a Revenue Crash<\/h2>\n\n\n\n

Understanding how revenue collapses under generic pressure requires looking at actual case histories rather than stylized models. Three cases illustrate the range of outcomes and the factors that determine them.<\/p>\n\n\n\n

Lipitor: The Largest Single Revenue Cliff in Drug History<\/h3>\n\n\n\n

Atorvastatin (Lipitor) was the world’s best-selling drug for most of the 2000s, with peak annual revenues exceeding $12 billion globally. Pfizer’s IP strategy for Lipitor was multi-layered: the compound patent expired in March 2010, but Pfizer obtained a six-month pediatric exclusivity extension that pushed effective US generic entry to November 2011. Pfizer also listed several additional patents in the Orange Book covering the calcium salt form of atorvastatin and the enantiomerically pure form.<\/p>\n\n\n\n

Ranbaxy, the first ANDA filer on atorvastatin, had already settled its Paragraph IV litigation with Pfizer in 2008 under an agreement that granted Ranbaxy a license to sell authorized generic atorvastatin starting November 30, 2011\u2014the same date its 180-day exclusivity period began. Pfizer also sold its own authorized generic through Greenstone, a Pfizer subsidiary.<\/p>\n\n\n\n

The result was a flood of generic entry from day one. Within weeks, generic atorvastatin had captured 80% of new prescriptions. Within six months, branded Lipitor’s US market share had fallen to single digits. Pfizer’s US Lipitor revenues dropped from $5.9 billion in 2011 to $1.1 billion in 2013 [1]. The authorized generic generated some revenue but at substantially lower margins.<\/p>\n\n\n\n

The Lipitor story illustrates that even an aggressive IP strategy\u2014with pediatric exclusivity, multiple Orange Book-listed patents, and authorized generic deployment\u2014cannot prevent a near-total revenue collapse when the foundational compound patent expires and the drug is in a crowded, high-demand therapeutic category.<\/p>\n\n\n\n

Humira: The Biosimilar Delay That Bought a Decade<\/h3>\n\n\n\n

AbbVie’s adalimumab (Humira) strategy represents the most sophisticated pharmaceutical patent thicket ever constructed. The drug’s original compound patent expired in the United States in December 2016. US biosimilar competition did not arrive until January 2023\u2014more than six years later [4]. That delay generated an estimated additional $100 billion or more in US revenue for AbbVie.<\/p>\n\n\n\n

How? AbbVie filed approximately 250 patents covering Humira, protecting not just the antibody sequence but dozens of formulation characteristics, manufacturing processes, device features (including the auto-injector pen design), and method-of-use claims. As each biosimilar developer approached commercialization, AbbVie filed patent infringement suits. Most biosimilar developers ultimately settled with AbbVie, accepting license agreements that allowed them to enter the US market in January 2023\u2014years after European biosimilar competition had already compressed margins overseas.<\/p>\n\n\n\n

The contrast between US and European Humira competition is instructive. In Europe, where the litigation and settlement economics differ and where “patent linkage” between patent disputes and regulatory approval does not operate the same way, Amgen’s Amgevita and other biosimilars launched in October 2018. European adalimumab revenues fell sharply. US revenues continued growing through 2022 before the January 2023 launch wave began.<\/p>\n\n\n\n

AbbVie’s 2023 annual report showed US Humira net revenues declining from $17.6 billion in 2022 to $11.2 billion in 2023, a 36% drop [2]. By 2024, the decline continued as formularies shifted toward lower-cost biosimilars and interchangeable status proliferated. The thicket did not stop the cliff\u2014it relocated it in time, by approximately six years.<\/p>\n\n\n\n

AstraZeneca and Seroquel: What Thicket Defense Actually Costs<\/h3>\n\n\n\n

Quetiapine fumarate (Seroquel) and its extended-release formulation (Seroquel XR) offer a more cautionary case. AstraZeneca’s IP strategy included compound patents, formulation patents on the extended-release matrix, and Orange Book listings that generated multiple 30-month stays against generic applicants. AstraZeneca also pursued a “product hop”\u2014shifting its commercial and marketing focus toward Seroquel XR before the immediate-release formulation’s exclusivity expired, hoping to migrate patients to the better-protected extended-release version.<\/p>\n\n\n\n

The strategy had mixed results. Generic quetiapine IR launched in 2012, and the immediate-release Seroquel market largely collapsed. Seroquel XR maintained stronger sales for a period, but generics for the XR formulation followed in 2016. AstraZeneca’s total quetiapine revenues fell from approximately $5.5 billion in 2011 to less than $1 billion by 2016 [5]. The product hop bought roughly four additional years of protected XR revenue\u2014meaningful value, but the cliff was not avoided.<\/p>\n\n\n\n

The lesson is not that product hops fail. The lesson is that they succeed only when clinically meaningful differentiation supports the commercial shift. If physicians and patients perceive no real benefit from the new formulation, managed care organizations will treat the switch as purely economic and resist it. If there is genuine clinical differentiation\u2014better tolerability, reduced dosing frequency, measurable efficacy improvements\u2014the migration is more durable.<\/p>\n\n\n\n

\n\n\n\n

Mapping Your Patent Exposure: A Four-Step Framework<\/h2>\n\n\n\n

Before you can defend revenue, you need to know what you are actually defending and for how long. This requires systematic mapping of your patent estate across all marketed products and late-stage pipeline assets. Most large pharma companies have internal IP analytics teams that perform this function. Smaller organizations often lack the resources and end up making critical life cycle management decisions based on incomplete information.<\/p>\n\n\n\n

The following four-step framework is designed to produce a clear picture of your IP position and the timeline of potential revenue events.<\/p>\n\n\n\n

Step 1: Build Your IP Inventory<\/h3>\n\n\n\n

The starting point is a complete patent inventory for each product. This means every patent\u2014US and international\u2014that is or could be relevant to product protection. The inventory should capture the patent number, title, filing date, issue date, expiration date (accounting for patent term extension claims, terminal disclaimers, and any regulatory exclusivity periods), claim scope at a high level, and Orange Book listing status.<\/p>\n\n\n\n

For US products, the FDA’s Orange Book is the authoritative source for listed patents, but it is not a complete IP picture. Patents that do not meet the Orange Book listing criteria (which requires covering the drug substance, drug product, or method of use) still exist and may be relevant to enforcement strategy or to understanding a competitor’s exposure. Similarly, patents filed but not yet issued may provide important future protection that does not appear in any current database.<\/p>\n\n\n\n

Platforms like DrugPatentWatch aggregate FDA Orange Book data, PTAB docket information, ANDA filing records, and expiration date calculations into searchable dashboards. Analysts use DrugPatentWatch to map competitor patent positions, track new Paragraph IV certifications against specific drugs, and monitor PTAB inter partes review petitions filed against Orange Book-listed patents. The platform does not replace legal analysis, but it dramatically accelerates the initial mapping process and provides a baseline that internal teams can refine.<\/p>\n\n\n\n

Step 2: Identify Expiration Cascades<\/h3>\n\n\n\n

A single patent expiration date is less useful than understanding the sequence in which your layered protections expire. The relevant concept is the “exclusivity waterfall”\u2014the chronological schedule of patent and regulatory exclusivity expirations across all protection layers for a given product.<\/p>\n\n\n\n

Build the waterfall by listing every relevant patent with its expiration date. Then overlay regulatory exclusivity periods: five-year new chemical entity (NCE) exclusivity for newly approved small molecules, three-year exclusivity for new clinical investigations, seven-year orphan drug exclusivity, and the relevant biologic exclusivity periods. The resulting timeline tells you when each barrier to generic entry falls, which gives you a rough model of when revenue events might occur.<\/p>\n\n\n\n

The critical insight is that the protection schedule is rarely linear. Compound patents expire first, but formulation and method-of-use patents may extend protection for several additional years. The question is not just when protection ends but what percentage of your revenue relies on any given layer. A compound patent covering a blockbuster small molecule is protecting the entire product; a method-of-use patent covering a specific indication may protect a minority of your prescriptions.<\/p>\n\n\n\n

Map the revenue associated with each protected indication and formulation. This gives you a revenue-at-risk figure for each expiration date rather than a single undifferentiated cliff.<\/p>\n\n\n\n

Step 3: Stress-Test Each Layer Against Invalidity Risk<\/h3>\n\n\n\n

Knowing that a patent expires in 2031 does not tell you whether it will survive a validity challenge between now and then. PTAB inter partes review (IPR) proceedings have invalidated a substantial portion of challenged pharmaceutical patents. According to USPTO data, IPR petitions in the pharmaceutical and life sciences sector have resulted in at least one claim being invalidated in approximately 70-75% of cases that reach a final written decision [6].<\/p>\n\n\n\n

Stress-testing your portfolio means assessing the invalidity risk of each patent in your thicket. This is ultimately a legal judgment, but it can be structured around a set of specific questions:<\/p>\n\n\n\n

For obviousness: Is there prior art that teaches all the key elements of the claim? Could a person of ordinary skill in the art have been motivated to combine the relevant prior art elements? The KSR framework, which the Supreme Court adopted in 2007, broadly expanded the range of combinations that can be deemed obvious [7]. Formulation patents are particularly vulnerable because the building blocks of pharmaceutical formulations are well-known and combination approaches are often documented in the literature.<\/p>\n\n\n\n

For written description and enablement: Do the examples in the specification actually support the full scope of the claims as written? Broad genus claims on antibodies, for example, came under severe pressure in the Amgen v. Sanofi decision, where the Supreme Court unanimously held in 2023 that Amgen’s broad antibody claims were invalid for lack of enablement because the specification did not teach practitioners how to make and use all members of the claimed genus [8]. The Amgen decision has particular implications for biologics patent portfolios that rely on broad functional claims.<\/p>\n\n\n\n

For patent term extension claims: Are your PTE claims properly supported and documented? PTE applications are complex and errors can result in less extension than anticipated or none at all.<\/p>\n\n\n\n

This stress-testing should produce a qualitative invalidity risk rating\u2014low, medium, or high\u2014for each patent in the waterfall. High-risk patents should be treated as potentially expiring early rather than on their nominal expiration dates.<\/p>\n\n\n\n

Step 4: Model the Revenue Scenarios<\/h3>\n\n\n\n

With an IP inventory, an expiration waterfall, and invalidity risk assessments in hand, you can build a set of revenue scenarios. This is financial modeling tied to specific patent events.<\/p>\n\n\n\n

The base case assumes each patent survives to its nominal expiration date and that generic or biosimilar entry follows expiration by six to twelve months. The downside case assumes that high-risk patents are successfully challenged one to three years before expiration and that aggressive generic entry follows. The upside case models successful patent defense across all layers combined with life cycle management that migrates revenue to next-generation products before the cliff arrives.<\/p>\n\n\n\n

For each scenario, model the revenue at risk on an annual basis, the probability weight each scenario, and derive an expected present value for the protected revenue stream. This output is what business development and corporate strategy teams need to evaluate partnership opportunities, acquisition targets, and internal R&D resource allocation.<\/p>\n\n\n\n

\n\n\n\n

The Tools That Matter for Competitive Intelligence<\/h2>\n\n\n\n

DrugPatentWatch and How Analysts Use It<\/h3>\n\n\n\n

Patent mapping in pharmaceuticals requires synthesizing information from multiple databases: the FDA Orange Book, USPTO patent records, PTAB dockets, ANDA approval records, and court filings. DrugPatentWatch synthesizes much of this into a unified view that analysts can use without pulling raw data from each source separately.<\/p>\n\n\n\n

For any branded drug, DrugPatentWatch provides a list of Orange Book-listed patents with expiration dates, a list of known ANDA filers and their certification types, and alerts on new Paragraph IV certifications\u2014the key signal that a generic company is preparing to challenge your IP. The platform also tracks first-to-file 180-day exclusivity status, which determines which generic manufacturer gets the earliest market access.<\/p>\n\n\n\n

Competitive intelligence teams use DrugPatentWatch to monitor what generic companies are filing against competitors’ drugs, which provides early warning of where generic interest is clustering. If three different generic manufacturers file ANDAs with Paragraph IV certifications against a competitor’s drug in the same quarter, that is strong evidence that the competitor’s IP position is perceived as weak. The same logic applies to your own portfolio: a wave of Paragraph IV certifications is the clearest signal that your thicket is being probed for entry points.<\/p>\n\n\n\n

For biosimilars, the parallel tool is the Purple Book, which tracks reference biologics and biosimilar applications. DrugPatentWatch also covers the biosimilar patent dance process\u2014the statutory information exchange under the Biologics Price Competition and Innovation Act (BPCIA) that governs how reference product sponsors and biosimilar applicants share and contest patent lists.<\/p>\n\n\n\n

Orange Book vs. Purple Book: What They Tell You<\/h3>\n\n\n\n

The Orange Book lists patents covering small-molecule drugs approved under New Drug Applications (NDAs). It has several important constraints. First, listing is limited to patents covering the drug substance, drug product, or method of use\u2014other patents, even if relevant to the product, are not listed. Second, listing creates legal obligations: a patent must be listed promptly after approval, and listing a patent that does not meet the criteria is a form of misconduct that can expose the NDA holder to antitrust claims. Third, the Orange Book does not indicate whether any listed patent has been challenged or is under litigation.<\/p>\n\n\n\n

The Purple Book tracks biologic products approved under Biologics License Applications (BLAs). It is less directly tied to the patent dispute mechanism than the Orange Book\u2014the BPCIA patent dance operates separately from the listing regime. The Purple Book does indicate which products have been designated as reference products, which biosimilars have been approved, and which have been granted interchangeable designation (the higher standard that allows pharmacist substitution without prescriber authorization).<\/p>\n\n\n\n

Understanding these databases as competitive tools requires recognizing what they do not show. They do not show patents that are relevant to a product but not listed (because they cover processes or other non-listing-eligible aspects). They do not show patent applications that have not yet issued. And they do not show the settlement terms of litigation that has been resolved, which are often confidential and contain commercially significant information about launch timing and licensing terms.<\/p>\n\n\n\n

PTAB and IPR as a Competitive Weapon<\/h3>\n\n\n\n

The Patent Trial and Appeal Board is where patent thickets are tested under fire. Inter partes review allows any party to petition PTAB to review issued patents on grounds of anticipation or obviousness based on prior art patents and printed publications. The proceedings are faster than district court litigation\u2014typically concluded within 18 months of institution\u2014and cheaper, usually in the range of $500,000 to $2 million per proceeding compared to $10 million or more for district court trials.<\/p>\n\n\n\n

For generic and biosimilar challengers, IPR has become a standard component of the patent challenge strategy. It does not replace Paragraph IV litigation\u2014the two proceedings can run in parallel\u2014but it creates an additional avenue for invalidating patents that block market entry. A successful IPR petition that invalidates key Orange Book-listed patents can collapse a 30-month stay and open the market years earlier than the originator planned.<\/p>\n\n\n\n

For originator companies, the existence of PTAB means that the strength of any individual patent is better assessed against the IPR standard than against the older district court standard. The IPR standard for claim construction is different, the process is faster, and PTAB judges are technically sophisticated. Patents that would have survived district court challenges in the pre-AIA era may not survive IPR. This should inform how you think about the robustness of your thicket.<\/p>\n\n\n\n

Monitoring PTAB dockets for petitions filed against your patents\u2014and against competitors’ patents\u2014is essential for understanding where the competitive landscape is shifting. New petitions are public records, and the institution decision (whether PTAB agrees to review the petition) provides an early signal of patent strength. Petitions that are denied institution tend to correlate with patents that were later upheld in district court litigation.<\/p>\n\n\n\n

\n\n\n\n

Legal Strategies That Work (and Some That Don’t)<\/h2>\n\n\n\n

Authorized Generics: The Double-Edged Sword<\/h3>\n\n\n\n

An authorized generic is a version of a branded drug sold under the brand’s NDA but marketed at generic prices, typically through a subsidiary or licensing partner. When the first ANDA filer obtains its 180-day exclusivity period, the only competition to the authorized generic is that single company. This is a significant commercial advantage over the later waves of full generic competition.<\/p>\n\n\n\n

Pfizer’s use of Greenstone to sell authorized generic atorvastatin on the day of Lipitor’s patent expiration illustrates the strategy. Authorized generics disrupt the first-to-file generic company’s exclusivity period, which reduces the financial incentive that the 180-day exclusivity was designed to create for generic challengers. This is precisely why generic companies and some consumer groups have argued that authorized generics undermine the Hatch-Waxman Act’s intent.<\/p>\n\n\n\n

The Federal Trade Commission has studied authorized generic use and found that they reduce prices for consumers during the exclusivity period while reducing the commercial value of 180-day exclusivity for the generic challenger [9]. From the originator’s perspective, the trade-off is between capturing some revenue during the exclusivity window (which would otherwise go entirely to the generic company) and potentially deterring future Paragraph IV challenges. If generic companies know that originator companies will always deploy authorized generics to undercut their exclusivity period, they may be less motivated to invest in expensive litigation challenges.<\/p>\n\n\n\n

Authorized generics work best when the 180-day exclusivity would otherwise represent a large revenue transfer to a competitor. They are less useful when the product has multiple ANDA filers with staggered exclusivity\u2014because authorized generics compete equally against the third and fourth generic entrants as against the first.<\/p>\n\n\n\n

Pay-for-Delay: The Shrinking Option<\/h3>\n\n\n\n

Reverse payment settlements\u2014where the originator pays the generic challenger to delay launch\u2014were a standard tool of pharmaceutical settlement practice until the Supreme Court’s 2013 decision in FTC v. Actavis [10]. The Court held that reverse payment settlements are subject to antitrust scrutiny under the rule of reason. They are not per se illegal, but they can be challenged as anticompetitive if the payment is large and the delay is substantial.<\/p>\n\n\n\n

Since Actavis, reverse payment settlements have become more carefully structured and less common in their naked “cash for delay” form. Originators have used “no-cash” settlements that provide value to the generic company through licensing rights, royalty-free sales in non-core markets, or supply agreements\u2014structures designed to provide economic value without creating a visible reverse payment. The FTC continues to scrutinize these arrangements, and litigation over post-Actavis settlement structures has produced an evolving body of case law.<\/p>\n\n\n\n

For practical purposes, pay-for-delay in any form carries significant antitrust exposure. Companies that rely on reverse payment settlements as a primary defense strategy are taking on legal risk that can result in treble damages and injunctive relief. Structured licensing agreements and authorized generic arrangements that also provide commercial value to generic partners may serve similar commercial purposes with less legal risk\u2014but they require careful antitrust counsel.<\/p>\n\n\n\n

Patent Term Extensions and Pediatric Exclusivity<\/h3>\n\n\n\n

The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) provides for patent term extension to compensate for the time a drug spends in regulatory review after the patent is filed. A PTE can extend a patent by up to five years, with the extended term not exceeding fourteen years from approval. Only one patent per drug product is eligible for PTE, and the applicant must elect which patent to extend.<\/p>\n\n\n\n

The strategic choice of which patent to extend matters. If the compound patent is already short, extending it may provide more time than extending a later-filed formulation patent. But if the formulation patent expires after the compound patent’s extended term, the two might be scheduled to expire close together. The optimal election depends on the full patent landscape and the relative commercial importance of the claims in each patent.<\/p>\n\n\n\n

Pediatric exclusivity adds six months of market exclusivity for any existing exclusivity or patent protection, provided the NDA holder conducts pediatric studies in response to a written request from FDA. It applies to all pending patents and exclusivities associated with the drug\u2014not just the one for which pediatric studies were conducted. This made pediatric exclusivity a significant tool for products with substantial adult markets, because a relatively modest investment in pediatric studies could generate six months of protection on billions of dollars of annual revenue.<\/p>\n\n\n\n

Lipitor’s November 2011 cliff (rather than the March 2010 compound patent expiration) was a direct product of pediatric exclusivity. Pfizer conducted the required pediatric studies and received six months of additional exclusivity on top of its existing patent protection. On a drug generating nearly $6 billion in annual US revenues, six months was worth approximately $3 billion in preserved branded revenue.<\/p>\n\n\n\n

Citizen Petitions as Delay Tactics<\/h3>\n\n\n\n

FDA’s citizen petition process allows any party to petition the agency to take or refrain from taking a specific action. Originator companies have used citizen petitions to argue that FDA should require additional studies before approving an ANDA\u2014typically scientific arguments about bioequivalence standards, dosing, or patient safety concerns.<\/p>\n\n\n\n

The regulatory history on citizen petitions as delay tactics is contentious. Congress passed the FDA Amendments Act of 2007, which authorized FDA to deny any petition that would delay approval if the petition does not raise valid scientific issues [11]. FDA now routinely denies “last-minute” petitions that appear designed primarily to delay competitive entry. Courts have found that some citizen petition filings violate antitrust law when they represent sham petitions with no legitimate scientific basis.<\/p>\n\n\n\n

Citizen petitions remain a legitimate tool when they raise genuine scientific questions about the adequacy of a generic’s characterization of bioequivalence or safety. They are not a reliable standalone defense strategy and carry reputational and antitrust risks when used primarily as delay mechanisms.<\/p>\n\n\n\n

\n\n\n\n

Product Life Cycle Management: What Works<\/h2>\n\n\n\n

Life cycle management (LCM) is the set of clinical, regulatory, formulation, and commercial strategies designed to extend a product’s revenue-generating life beyond the expiration of its foundational patents. When executed well, LCM creates a revenue bridge that allows the portfolio to transition from one protected product to the next without a catastrophic cliff.<\/p>\n\n\n\n

Reformulation Strategies<\/h3>\n\n\n\n

The most common LCM strategy is reformulation\u2014developing a modified version of the existing product that offers clinical or convenience advantages and which carries later-expiring patents. Extended-release formulations, abuse-deterrent formulations, and fixed-dose combinations are standard examples.<\/p>\n\n\n\n

The commercial success of a reformulation depends on whether it offers something that prescribers and patients actually want. Extended-release formulations that allow once-daily dosing have genuine adherence advantages for chronic conditions. Abuse-deterrent formulations carry a public health rationale that supports formulary placement and, in some cases, regulatory designation. Fixed-dose combinations reduce pill burden for patients on multiple agents in the same therapeutic category.<\/p>\n\n\n\n

Where reformulation fails is when the new product is perceived as clinically equivalent to the old one\u2014or when it is identical in all respects except price. The “product hop” literature in pharmaceutical economics documents cases where companies discontinued the original formulation and promoted the new one not because of clinical benefits but to capture patients before generic entry on the original. Courts and regulators have shown increasing skepticism toward product hops that appear designed primarily to suppress generic competition rather than serve patient needs.<\/p>\n\n\n\n

The Namenda XR case illustrates the risk. Forest Laboratories announced plans to discontinue Namenda IR (immediate-release memantine) in advance of generic entry, forcing patients to convert to Namenda XR. A federal district court issued a preliminary injunction blocking the discontinuation, holding that it was likely anticompetitive [12]. The Second Circuit affirmed. The lesson: product hops that require patients to switch rather than encouraging voluntary adoption may cross antitrust lines, particularly when the discontinuation of the original product is timed to coincide with generic entry.<\/p>\n\n\n\n

Combination Products<\/h3>\n\n\n\n

Fixed-dose combination (FDC) products combine two or more active ingredients in a single dosage form. They are used widely in cardiovascular disease, HIV\/AIDS, diabetes, and respiratory medicine. From an IP perspective, combinations can be protected by patents on the specific combination, the formulation, the dosing ratio, or the methods of use\u2014all of which may expire after the individual component patents.<\/p>\n\n\n\n

The cardiovascular sector offers instructive examples. Once statins became generic, originator companies developed fixed-dose combinations of statins with other cardiovascular agents: Vytorin (ezetimibe\/simvastatin), Caduet (amlodipine\/atorvastatin), and others. The commercial success of these combinations depended on whether they offered prescribers a genuine simplification and whether managed care organizations were willing to pay combination prices rather than directing patients to simultaneous generic prescribing. Results were mixed. Caduet struggled commercially; Vytorin achieved moderate success before its own intellectual property ran its course.<\/p>\n\n\n\n

For LCM purposes, FDC products are most valuable when they combine the company’s own branded agent with a high-quality generic (providing a meaningful convenience advantage) and when prescriber preferences support combination therapy over separate agents.<\/p>\n\n\n\n

Indication Expansion<\/h3>\n\n\n\n

Expanding into new indications generates method-of-use patents that expire later than the foundational patents and also creates new revenue streams from different patient populations. More importantly, a drug approved for additional indications becomes harder to substitute away from, because different prescribers across different specialties become familiar with the brand, and label-specific claims remain valid until the method-of-use patents on those indications expire.<\/p>\n\n\n\n

Indication expansion requires clinical investment\u2014randomized controlled trials, regulatory submissions, and label-modification processes. But the return on investment can be substantial when the new indication has significant market size and when the competitive landscape in that indication is favorable.<\/p>\n\n\n\n

Repatha (evolocumab) and Praluent (alirocumab), the PCSK9 inhibitors, illustrate how indication expansion into high-risk cardiovascular prevention extended IP-relevant differentiation even as the original lipid-lowering indication became commercially contested. The cardiovascular outcome trial data, published in 2017 and 2018 respectively, generated method-of-use data for specific high-risk populations that supported additional patent filings and created clinical differentiation that generic antibodies could not immediately replicate.<\/p>\n\n\n\n

The Next-Generation Molecule<\/h3>\n\n\n\n

The most strategically robust LCM approach is developing a next-generation molecule that offers genuine clinical advantages\u2014improved potency, selectivity, tolerability, or dosing convenience\u2014and that carries a fresh 20-year patent clock from its compound patent. The next-gen molecule effectively phases out the original product before generic entry becomes commercially dominant, because prescribers have already migrated to the new product.<\/p>\n\n\n\n

AstraZeneca executed this well in the proton pump inhibitor category. Prilosec (omeprazole) was facing patent expiration when AstraZeneca developed esomeprazole (Nexium)\u2014the S-enantiomer of omeprazole\u2014and aggressively promoted the switch. Whether esomeprazole actually offered clinically meaningful advantages over omeprazole became the subject of intense scientific and commercial debate, but the migration succeeded commercially. Nexium became one of the best-selling drugs in the world, generating revenue for years after generic omeprazole flooded the market [13].<\/p>\n\n\n\n

The critics argued, and many physicians agreed, that esomeprazole’s clinical advantages over generic omeprazole were modest relative to its price premium. Managed care organizations eventually restricted coverage. But by the time esomeprazole faced significant pricing pressure, it had generated many billions in revenue that would otherwise have been lost to omeprazole generics.<\/p>\n\n\n\n

\n\n\n\n

Biosimilars: A Different Kind of Battle<\/h2>\n\n\n\n

The patent landscape for biologics is fundamentally different from small molecules in ways that affect both how thickets are built and how they fail.<\/p>\n\n\n\n

Why the Biologics Playbook Diverges<\/h3>\n\n\n\n

Small-molecule drugs are synthesized through defined chemical processes. Two different manufacturers using the same process can produce molecules that are analytically identical\u2014or close enough that bioequivalence can be demonstrated in standard pharmacokinetic studies. This is why generic small-molecule drug approval under Hatch-Waxman relies on a relatively straightforward bioequivalence standard.<\/p>\n\n\n\n

Biologics\u2014proteins, monoclonal antibodies, fusion proteins, blood factors\u2014are produced by living cells. The manufacturing process is integral to the product. Subtle differences in cell line, media, purification, and storage can produce molecules that are analytically similar but not identical. This is why biosimilars are not “generic biologics” in the Hatch-Waxman sense. They are required to demonstrate biosimilarity through a more extensive data package, and interchangeable status (allowing pharmacist substitution without prescriber authorization) requires additional switching studies.<\/p>\n\n\n\n

The greater complexity of biologic characterization means that the patent landscape for biologics is more complex as well. It is not just compound structure. It includes manufacturing process patents, formulation stability patents, device patents (for autoinjectors and prefilled syringes), and method-of-use patents covering specific dosing regimens and patient populations.<\/p>\n\n\n\n

The 12-Year Exclusivity Window and Its Real-World Limits<\/h3>\n\n\n\n

The Biologics Price Competition and Innovation Act provides 12 years of data exclusivity for new reference biologics\u2014meaning FDA cannot approve a biosimilar until 12 years after the reference biologic’s approval, even if all relevant patents have expired or been invalidated. This is a regulatory exclusivity separate from patent protection.<\/p>\n\n\n\n

But the 12-year clock begins at initial US approval, and biologics are often approved while patents are still many years from expiration. For Humira, approved in 2002, the 12-year exclusivity expired in 2014. The patent thicket, not the regulatory exclusivity, drove the delay to 2023. For other biologics where the patent portfolio is thinner, the 12-year clock may be the binding constraint.<\/p>\n\n\n\n

The real-world limit on the 12-year exclusivity is that it applies only to the specific product formulation and indication at initial approval. For extended indications approved after the initial BLA, there is no additional 12-year exclusivity. And the exclusivity does not prevent biosimilar approval based on reference to the original BLA\u2014it just creates a waiting period for regulatory approval, which biosimilar developers can use for manufacturing scale-up and litigation preparation.<\/p>\n\n\n\n

Stacking Patents on Biologics: AbbVie’s Playbook<\/h3>\n\n\n\n

AbbVie’s strategy with Humira has been studied extensively as a case study in aggressive biologic patent accumulation. The approximately 250 patents covering Humira were not all filed simultaneously; they were filed incrementally over more than a decade as AbbVie refined formulations, developed new device presentations, and obtained regulatory approval for additional indications.<\/p>\n\n\n\n

The key feature of the strategy was that it targeted every aspect of the drug that could be covered by a patent claim\u2014not just the obvious targets like the antibody sequence and formulation. Auto-injector design patents, concentration-specific formulation patents (covering the switch from the original 40mg\/0.8mL formulation to the high-concentration 40mg\/0.4mL citrate-free formulation), and manufacturing process patents all contributed to a portfolio that was too large for any single biosimilar developer to challenge comprehensively.<\/p>\n\n\n\n

The citrate-free reformulation deserves particular attention as an LCM strategy. AbbVie developed a version of adalimumab with lower citrate concentration, which reduced injection-site pain\u2014a real clinical benefit that patients noticed. This reformulation generated new patents and allowed AbbVie to shift prescribers to the newer formulation before biosimilar entry. Biosimilar developers who had characterized their products against the original formulation had to assess whether their biosimilarity data bridged to the new formulation. This created additional uncertainty that delayed commercial launch.<\/p>\n\n\n\n

The post-Amgen v. Sanofi environment makes broad functional genus claims on antibodies more difficult to sustain. Future biologic patent portfolios will need to rely more heavily on specific formulation, device, and method-of-use claims rather than on broad antibody class claims.<\/p>\n\n\n\n

\n\n\n\n

Building a Thicket That Survives IPR<\/h2>\n\n\n\n

Claim Breadth vs. Claim Defensibility<\/h3>\n\n\n\n

The fundamental tension in pharmaceutical patent drafting is between claim breadth and claim defensibility. Broad claims\u2014covering a wide genus of compounds, a wide range of formulation parameters, or a broad clinical population\u2014provide the most comprehensive protection but are most vulnerable to obviousness and enablement challenges. Narrow claims provide more certainty of survival but protect less.<\/p>\n\n\n\n

The practical approach is layered claim architecture: broad independent claims that cover as much as the specification can support, with progressively narrower dependent claims that create fallback positions if the broader claims are challenged. If an IPR proceeding invalidates the broad independent claim, the narrower dependent claims may survive\u2014providing reduced but real protection.<\/p>\n\n\n\n

What makes a claim defensible in IPR? Several factors matter in practice. First, the quality of the experimental data in the specification: claims supported by specific examples with quantified results are harder to attack as enabling broad generalizations without support. Second, the quality of the prior art search at prosecution: if you know the closest prior art and can distinguish it in the claims or prosecution history, an IPR petitioner has a harder time constructing a convincing obviousness argument. Third, secondary considerations of non-obviousness: evidence of commercial success, long-felt unmet need, failure of others, and unexpected results can rebut a prima facie case of obviousness.<\/p>\n\n\n\n

Written Description and Enablement Risks<\/h3>\n\n\n\n

The Amgen v. Sanofi decision in 2023 hardened the enablement standard for genus claims on functional antibodies [8]. The Court applied a simple test: does the specification enable the full scope of the claims as written? If the claim covers a broad genus of antibodies defined by their function (binding to PCSK9 and blocking LDL receptor binding), and the specification only describes a small number of specific antibodies, the claim may not be enabled\u2014because practitioners would need to engage in undue experimentation to identify all antibodies that fall within the functional genus.<\/p>\n\n\n\n

This has specific implications for how to draft biologic patents post-Amgen. Claims should be scoped to what the specification actually teaches. If you can only describe a handful of antibody sequences, claim those specific sequences with appropriate breadth for variants and derivatives, rather than claiming all antibodies that perform a defined function. The protection is narrower but more durable.<\/p>\n\n\n\n

For small molecules, the written description and enablement issues are less severe for compound patents\u2014where the compound is structurally defined\u2014but arise more frequently for method-of-use claims covering broad patient populations or treatment conditions that are not specifically tested in the specification.<\/p>\n\n\n\n

How to Anticipate PTAB Challenges<\/h3>\n\n\n\n

The best defense against an IPR petition is preparation before the petition is filed. This means conducting your own IPR-style prior art search at the time of prosecution, identifying the claims most likely to be challenged, and either narrowing them before issuance or building the experimental record that would rebut the expected challenge.<\/p>\n\n\n\n

After issuance, monitoring PTAB dockets for petitions against similar patents in your therapeutic category gives advance warning of the arguments that are being advanced. If an IPR petitioner successfully argues that a particular type of polymer excipient renders extended-release matrix formulation claims obvious, that argument is now public and may be turned against your similar claims.<\/p>\n\n\n\n

For Orange Book-listed patents that are targeted by Paragraph IV certifications, PTAB proceedings against those patents can be coordinated with district court litigation strategy. If PTAB issues a final written decision upholding the patents before the district court reaches the same question, it creates estoppel that prevents the petitioner from re-litigating the same grounds. If PTAB invalidates claims before district court resolution, the litigation posture changes significantly.<\/p>\n\n\n\n

\n\n\n\n

The Regulatory Dimension<\/h2>\n\n\n\n

FDA Exclusivity vs. Patent Protection: Key Differences<\/h3>\n\n\n\n

FDA exclusivity and patent protection are parallel but distinct systems. Both can block generic approval, but they operate through different mechanisms and can be triggered and lost through different events.<\/p>\n\n\n\n

FDA exclusivity periods do not expire; they expire on specific dates calculated from the approval date, the date the pediatric study data was submitted, or another trigger. They cannot be extended by court order (unlike patent 30-month stays). They cannot be invalidated by PTAB. But they also do not cover all aspects of the product\u2014NCE exclusivity prevents any ANDA for five years, but after that period, a generic can be approved based on a bioequivalence showing without needing to address patents separately (unless the 30-month stay applies).<\/p>\n\n\n\n

Patent protection can extend for decades, can be layered across multiple patents, and can be enforced through litigation. But patents can be challenged, invalidated, and can expire before the commercial life of the product is over. The strategic interaction between FDA exclusivity and patent protection is often more nuanced than the simple “first barrier is FDA, second is patents” framing.<\/p>\n\n\n\n

For new drug approvals with NCE status, the five-year exclusivity acts as a complete bar to ANDA filing\u2014generics cannot even submit their applications until the exclusivity expires. This gives the originator five years to establish market position, build clinical evidence, and file additional IP. Once NCE exclusivity expires, the patent system takes over as the primary barrier.<\/p>\n\n\n\n

How 505(b)(2) Applications Create Opportunities<\/h3>\n\n\n\n

A 505(b)(2) NDA is a hybrid application used for reformulated products, new dosage forms, or new uses of approved drugs. It relies in part on published literature and FDA’s prior approval findings rather than requiring a complete clinical data package. This makes 505(b)(2) applications faster and cheaper to develop than full NDAs.<\/p>\n\n\n\n

For originator LCM strategies, 505(b)(2) is the vehicle for most reformulations and combination products. A new extended-release formulation, a new indication, or a new fixed-dose combination that relies on the well-established safety of the existing compound can go through the 505(b)(2) pathway.<\/p>\n\n\n\n

The strategic relevance is that 505(b)(2) approvals generate their own FDA exclusivities: three-year exclusivity for new clinical investigations (for the specific change), and potentially NCE exclusivity if the changed product is considered a new chemical entity. The 505(b)(2) product is listed separately in the Orange Book, with its own patent listings. This creates a new platform for Orange Book-listed patents that expire later than the original product’s IP.<\/p>\n\n\n\n

The Orange Book Listing and 30-Month Stays<\/h3>\n\n\n\n

The 30-month stay that flows from Paragraph IV litigation is one of the most commercially significant features of the Hatch-Waxman regime. When a generic company certifies that an Orange Book-listed patent is invalid or not infringed (Paragraph IV certification), it must give notice to the NDA holder and each patent holder. If the NDA holder files suit within 45 days, FDA approval is automatically stayed for 30 months or until final court determination.<\/p>\n\n\n\n

For a drug generating $5 billion in US revenues, a 30-month stay is worth approximately $12.5 billion in preserved revenue at that run rate\u2014enough to fully fund the litigation many times over. This is why originator companies file suit on virtually every Paragraph IV certification, regardless of the perceived strength of the generic’s invalidity arguments.<\/p>\n\n\n\n

The flip side is that 30-month stays can cascade. If the generic files against five Orange Book-listed patents simultaneously, five Paragraph IV certifications generate one 30-month stay (not five). The stay runs from the first suit filed. If the originator prevails in that suit, it may need to rely on other listed patents to sustain the stay or to restart litigation on different claims.<\/p>\n\n\n\n

The FDA Reauthorization Act of 2017 and subsequent FDA guidance have increased scrutiny on patent listing practices, and the FTC has pursued enforcement actions against what it characterizes as improper Orange Book listings\u2014particularly device patents for drug-device combination products. The appropriate scope of Orange Book listings continues to evolve.<\/p>\n\n\n\n

\n\n\n\n

Financial Modeling the Exclusivity Slope<\/h2>\n\n\n\n

Building a Patent Expiration Waterfall<\/h3>\n\n\n\n

A patent expiration waterfall is a visual and quantitative representation of how protection erodes over time across a drug’s IP portfolio. The horizontal axis is time (typically extending 15 to 20 years from the present); the vertical axis is percentage of protected revenue.<\/p>\n\n\n\n

At the leftmost point, the drug is under compound patent protection and fully protected. As the compound patent expires, the protection level drops to whatever is provided by the remaining formulation and method-of-use patents. These in turn expire at their nominal dates (adjusted for invalidity risk), reducing protection to zero\u2014or to whatever FDA regulatory exclusivity remains.<\/p>\n\n\n\n

The practical output is a revenue-at-risk schedule: year by year, what portion of the drug’s revenues could be exposed to generic competition if all patents in that protection band expired or were invalidated? This schedule drives capital allocation decisions. A drug with a step-function cliff in 2027 needs a different LCM investment than one with a gradual erosion over 2027-2032.<\/p>\n\n\n\n

Revenue at Risk Calculations<\/h3>\n\n\n\n

Revenue at risk is the expected present value of revenues that would be lost if generic entry occurs at each possible entry date. For each date, the calculation requires an estimate of generic penetration speed and depth, which varies by therapeutic category, payer mix, and the number of generic entrants.<\/p>\n\n\n\n

In highly competitive generic markets (statins, proton pump inhibitors, oral diabetes agents), generic penetration can reach 80-90% of prescription volume within six to twelve months of launch, with branded prices falling 40-80%. In less competitive markets\u2014rare diseases, complex dosage forms, narrow therapeutic categories\u2014generic penetration is slower and branded price erosion less severe.<\/p>\n\n\n\n

The modeling framework requires four inputs for each entry scenario: the year of expected generic entry, the expected number of generic entrants at launch, the category-level elasticity of branded price to generic competition, and the product-specific market share sensitivity to price differential. These inputs can be calibrated against historical data from comparable drug-generic events in the same therapeutic category.<\/p>\n\n\n\n

An important refinement is to model the revenue at risk separately for different distribution channels: commercial payer, Medicare Part D, Medicaid, and specialty pharmacy. Generic penetration rates differ significantly across channels. Medicaid programs use aggressive rebate and formulary mechanisms that drive very rapid generic substitution. Commercial payers in competitive markets respond almost as quickly. Medicare Part D beneficiaries who are price-sensitive shift quickly to preferred generic tiers; those in stable benefit designs may be slower to switch.<\/p>\n\n\n\n

The Value of Each Patent Layer<\/h3>\n\n\n\n

One analytically useful output of the waterfall model is the marginal value of each patent layer\u2014what each additional year of protection is worth in preserved revenue. This tells you how much to invest in defending or extending each patent.<\/p>\n\n\n\n

If compound patent expiration costs you $5 billion annually in lost branded revenues, and a formulation patent extends protection by two years, that patent is worth approximately $10 billion in present value (before discounting). Investing $30 million in vigorous defense of that formulation patent\u2014including through litigation, PTAB proceedings, and technical arguments\u2014is economically obvious. The same $30 million invested in defending a method-of-use patent that covers only 5% of prescriptions is a different calculation.<\/p>\n\n\n\n

This framework makes explicit what is often implicit in pharmaceutical IP strategy: not all patents are worth defending equally, and resource allocation should reflect the revenue at risk behind each layer.<\/p>\n\n\n\n

\n\n\n\n

What Generic Manufacturers Are Actually Doing<\/h2>\n\n\n\n

ANDA Filing Strategies<\/h3>\n\n\n\n

Generic manufacturers do not file ANDAs randomly. They focus on drugs with large revenue bases where patent challenges are likely to succeed, where the generic development program is technically feasible, and where the competitive dynamics are attractive\u2014meaning a limited number of other ANDA filers.<\/p>\n\n\n\n

The first ANDA filer with a Paragraph IV certification earns 180-day exclusivity if it wins the patent challenge (or if the originator’s patents are otherwise invalidated or expire). During the 180-day period, the first generic and the branded product are the only market participants; no other generic can be approved until the exclusivity expires. This is the financial prize that motivates aggressive patent challenges: 180-day exclusivity on a $1 billion drug is worth hundreds of millions of dollars, even at discounted generic prices.<\/p>\n\n\n\n

Generic companies conduct patent validity assessments before filing. They hire specialized patent counsel who review each Orange Book-listed patent, identify potential invalidity arguments, and assess the probability of success in litigation and IPR. They also assess the likelihood that the originator will sue within 45 days of the Paragraph IV notice, and they plan their development timeline accordingly. A generic that files an ANDA knowing litigation is certain but expects to prevail in court in 24-30 months can plan its manufacturing scale-up around a specific expected launch date.<\/p>\n\n\n\n

Tracking ANDA filings as a competitive intelligence signal requires monitoring FDA’s public disclosure of ANDA approval letters and, indirectly, tracking Paragraph IV certifications through patent litigation dockets. Court filings are public, and the filing of a Hatch-Waxman suit by a branded company is typically publicly disclosed within 45 days of the generic’s notification letter.<\/p>\n\n\n\n

Paragraph IV Certifications as Signals<\/h3>\n\n\n\n

A Paragraph IV certification is the clearest signal available that a generic company has assessed your IP as potentially vulnerable. The generic is certifying either that the patent is invalid or that its product will not infringe\u2014and is backing that position with the commitment to litigate if the originator sues.<\/p>\n\n\n\n

From a competitive intelligence perspective, the clustering of Paragraph IV certifications tells you which aspects of the IP portfolio the generic industry views as weak. If multiple generic companies certify against the same formulation patent while not certifying against the compound patent, that suggests the formulation patent is the perceived weakness. If they certify against method-of-use patents while seeking licenses under compound and formulation patents, that indicates a “skinny labeling” strategy.<\/p>\n\n\n\n

The first Paragraph IV certification on a drug is often a signal that others will follow. Once one generic company commits to challenging a patent position and paying the legal costs of developing the invalidity arguments, other generic companies can free-ride on those arguments (to some extent) in parallel litigation. The first challenger carries most of the discovery cost; subsequent challengers can leverage the work product developed in the first proceeding.<\/p>\n\n\n\n

Reading Generic Entry as a Competitive Intelligence Tool<\/h3>\n\n\n\n

Generic company activity against your competitors’ patents is as valuable as monitoring activity against your own. When Sun Pharmaceutical, Teva, or Viatris files ANDAs with Paragraph IV certifications against a competitor’s product, it tells you something about where that competitor’s IP is perceived as weak. This information is directly useful for corporate strategy\u2014it may indicate that a competitor is facing a revenue cliff earlier than the nominal patent expiration would suggest, which affects competitive dynamics in the therapeutic category.<\/p>\n\n\n\n

For business development purposes, a competitive intelligence view of generic ANDA activity across a therapeutic category can identify acquisition targets whose products are approaching their exclusivity cliffs, allowing a buyer to assess the residual value realistically and price the acquisition accordingly.<\/p>\n\n\n\n

\n\n\n\n

The New Exclusivity Slope: Structural Shifts in Patent Defense<\/h2>\n\n\n\n

AI-Assisted Patent Mining by Generic Firms<\/h3>\n\n\n\n

Generic manufacturers and their legal counsel now use AI tools to search prior art more comprehensively and more quickly than was possible five years ago. Large language models trained on patent databases, scientific literature, and clinical trial records can identify prior art references that human searchers would likely have missed\u2014references in obscure journals, patent applications in non-US jurisdictions that were never translated, or combinations of references that, read together, support an obviousness argument.<\/p>\n\n\n\n

This fundamentally changes the prior art landscape. Patents that survived prosecution because the prior art searcher missed a key Japanese patent application or a 1970s German journal article may now face IPR petitions based on references found by AI-assisted search. The strength of a patent should be assessed against this enhanced search capability, not against the historical standard.<\/p>\n\n\n\n

For originator companies, the implication is that prosecution should also use AI-assisted prior art search to ensure that the examiner’s search was thorough and that the strongest prior art is already cited and distinguished in the prosecution history. A patent with a clean prosecution history\u2014where the examiner clearly considered the closest prior art\u2014is more defensible in IPR than one where important references were not considered.<\/p>\n\n\n\n

Inter Partes Review Success Rates and What They Mean<\/h3>\n\n\n\n

USPTO data consistently show that pharmaceutical patents face invalidation in a significant fraction of IPR proceedings that reach final written decision. The exact percentage varies by technology class and claim type, but the general picture is that compound patents are more defensible than formulation patents, and formulation patents are more defensible than broad method-of-use patents. <blockquote> “According to USPTO statistics, pharmaceutical patent claims challenged in inter partes review proceedings faced partial or complete invalidation in approximately 73% of cases that reached a final written decision between 2012 and 2023.” [6] <\/blockquote><\/p>\n\n\n\n

This data should inform how you weight each patent in your waterfall model. A formulation patent with a 60% probability of surviving an IPR challenge should be modeled at 40% probability of providing the protection its expiration date nominally suggests. The revenue at risk calculation should weight these survival probabilities.<\/p>\n\n\n\n

The IPR statistics also inform portfolio construction. A thicket composed of ten patents each with a 60% survival probability provides much stronger aggregate protection than a thicket with three patents each at 80% probability\u2014because the probability that at least some protection survives is higher when the portfolio is diversified.<\/p>\n\n\n\n

The Post-Amgen Era for Biologics<\/h3>\n\n\n\n

Amgen v. Sanofi changes how broad antibody claims will be evaluated going forward. Combined with increasing biosimilar approvals and FDA’s growing sophistication in evaluating biosimilarity data, the post-Amgen biologic landscape is one where patent portfolios must work harder with narrower claims.<\/p>\n\n\n\n

Specifically, the focus of biologic patent portfolios will shift toward manufacturing process patents, specific formulation claims backed by extensive stability and bioavailability data, and device patents for administration systems. Method-of-use patents for specific patient populations\u2014backed by clinical trial data in those populations\u2014will continue to provide value, particularly where the biosimilar label carves out those indications.<\/p>\n\n\n\n

The commercial implication is that biologic manufacturers cannot rely on the kind of broad functional antibody claims that anchored the Humira thicket’s early layers. Each claim must be supported by specific experimental data, and the portfolio must be deeper and more granular to achieve comparable aggregate protection.<\/p>\n\n\n\n

\n\n\n\n

Building a Sustainable IP Portfolio<\/h2>\n\n\n\n

Portfolio Diversification Across Molecules<\/h3>\n\n\n\n

A single-product company that depends on one blockbuster drug is particularly vulnerable to a revenue cliff. The concentration risk is obvious: when the cliff arrives, there is no other protected product to absorb the revenue loss. Building a portfolio diversified across molecules with staggered exclusivity schedules smooths the revenue profile and reduces the impact of any single cliff.<\/p>\n\n\n\n

This sounds straightforward but is difficult to execute. Drug development fails frequently, and the cost of building a diversified pipeline is enormous. Large pharmaceutical companies manage this through a combination of internal R&D, acquisitions, and licensing. Smaller companies must make strategic choices about which therapeutic areas and mechanisms of action to focus on, recognizing that concentration creates vulnerability.<\/p>\n\n\n\n

From a financial modeling perspective, a portfolio with five products facing staggered exclusivity over a ten-year period has a much more predictable revenue profile than a portfolio with two products\u2014even if the total expected revenues are similar. The reduced uncertainty has real capital market value.<\/p>\n\n\n\n

Licensing as Revenue Insurance<\/h3>\n\n\n\n

Patent licensing can generate revenue from IP that would otherwise sit unused. Originator companies sometimes license their IP to authorized generics or to generic manufacturers in markets outside their strategic focus\u2014generating royalty income that partially offsets the revenue loss when generic entry occurs.<\/p>\n\n\n\n

More strategically, licensing can be used to capture revenue from applications of your technology that you are not developing yourself. A compound that is approved for one indication may have patent protection covering uses that other companies are developing in different applications. Licensing to those developers generates revenue and builds relationships that may support future collaboration.<\/p>\n\n\n\n

Licensing also has a defensive function: patent licenses granted to specific parties can be structured to restrict what those parties can do with the technology, which may limit the licensing partner’s ability to combine your IP with other technologies to create products that compete with your core business.<\/p>\n\n\n\n

Strategic Acquisitions to Extend the Pipeline<\/h3>\n\n\n\n

Acquisitions of companies or assets with patent-protected products at different stages of the exclusivity cycle can extend the period over which the portfolio generates meaningful protected revenues. If your primary product faces a cliff in 2027, acquiring a product with compound patent protection through 2033 adds five years to the period before the portfolio faces a combined cliff.<\/p>\n\n\n\n

The challenge with acquisition-driven pipeline extension is valuation. Products close to patent expiration are priced cheaply because the cash flows are short; assets with long exclusivity are expensive. The value of the acquisition depends critically on the validity of the target’s IP position\u2014which requires the same waterfall analysis, invalidity stress-testing, and revenue scenario modeling described above.<\/p>\n\n\n\n

Due diligence for pharmaceutical acquisitions now routinely includes an IP assessment that uses DrugPatentWatch and equivalent tools to assess the completeness of the target’s patent portfolio, identify any pending ANDA or biosimilar challenges, and estimate the timing and magnitude of potential revenue events. Buyers who skip this analysis are acquiring exposure without understanding it.<\/p>\n\n\n\n

\n\n\n\n

A Sector-Level View: The Pressure Is Systemic<\/h2>\n\n\n\n

The exclusivity slope facing the pharmaceutical industry is not a temporary phenomenon. It reflects structural changes in multiple dimensions simultaneously: the maturing of a generation of blockbuster drugs whose compound patents were filed in the 1990s and early 2000s; the increasing capability and aggressiveness of generic and biosimilar manufacturers; the strengthening of IPR as a patent challenge mechanism; and growing political and regulatory pressure on drug prices that makes the economic stakes of patent defense higher.<\/p>\n\n\n\n

The Inflation Reduction Act of 2022 introduced Medicare drug price negotiation for a select group of high-cost, patent-protected drugs without generic or biosimilar competition [14]. The first negotiated prices took effect in 2026. The drugs selected for negotiation are precisely those that have maintained high prices behind strong IP protection\u2014which means the IRA effectively shortens the commercial benefit of a successful patent thicket for drugs in its scope.<\/p>\n\n\n\n

For small molecules with nine years of post-approval market exclusivity without generic competition, the IRA triggers negotiation eligibility. For biologics, the threshold is thirteen years. This creates a new expiration clock that operates independently of the patent system and that cannot be extended through additional patent filings.<\/p>\n\n\n\n

The net effect is that the financial model for pharmaceutical IP protection needs to incorporate not just patent expiration dates but also IRA negotiation eligibility dates. A drug that is not yet facing generic competition in 2030 but becomes subject to Medicare negotiation in 2029 faces a revenue event that has some characteristics of a patent cliff\u2014a regulatory-driven price compression that is substantial even if the branded product maintains market share.<\/p>\n\n\n\n

This is not an argument that patent thickets have lost their value. They retain substantial value. But they now operate in a more complex environment where the ceiling on protected revenue is no longer set entirely by the patent system.<\/p>\n\n\n\n

\n\n\n\n

What CFOs and Business Development Leaders Need to Know<\/h2>\n\n\n\n

The translation of patent analytics into executive-level decision-making requires connecting the IP waterfall to financial planning in terms that non-patent specialists can evaluate.<\/p>\n\n\n\n

The key metric is “protected revenue duration”\u2014the number of years during which a product’s revenues are expected to remain substantially protected from generic or biosimilar competition. Protected revenue duration is a single number that summarizes the waterfall analysis, weighted by the survival probabilities of each patent layer and adjusted for IRA negotiation eligibility.<\/p>\n\n\n\n

For a drug generating $3 billion annually with a protected revenue duration of eight years, the present value of protected revenues (at a 10% discount rate) is approximately $16 billion. For the same drug with a protected revenue duration of five years, the present value drops to approximately $11.4 billion\u2014a $4.6 billion difference that should directly affect how much a buyer would pay for the asset in an acquisition or how much the company should invest in defending the IP.<\/p>\n\n\n\n

Business development teams should require an IP waterfall analysis and protected revenue duration estimate as part of the standard diligence package for any asset. External IP analytics platforms, legal counsel with pharmaceutical IP expertise, and commercial teams with experience in generic entry modeling can provide the inputs. The synthesis is a CFO-level conversation about capital allocation and portfolio risk.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/h2>\n\n\n\n

The 90% revenue crash is preventable\u2014but not with a single patent.<\/strong> Compound patents are the foundation of pharmaceutical IP protection, but they expire predictably and early. A strategy that relies only on the compound patent is a strategy for a cliff. The antidote is a layered portfolio of formulation, device, and method-of-use patents that collectively extend the protection schedule.<\/p>\n\n\n\n

IPR has permanently changed the risk calculus.<\/strong> Patents that survive FDA listing do not necessarily survive PTAB review. Approximately 73% of pharmaceutical patent claims challenged in IPR proceedings face at least partial invalidation. This means every patent in your portfolio should be stress-tested against the IPR standard\u2014not just the district court standard\u2014and invalidity probabilities should be incorporated into revenue scenario modeling.<\/p>\n\n\n\n

Biosimilar patent strategy post-Amgen requires narrower, better-supported claims.<\/strong> Broad functional antibody genus claims are no longer reliable anchors for biologic patent portfolios. The focus shifts to specific formulation claims, manufacturing process protection, device patents, and method-of-use claims backed by specific clinical trial data.<\/p>\n\n\n\n

Thickets buy time; they do not buy permanent protection.<\/strong> Humira’s thicket bought six years of US market exclusivity beyond the compound patent expiration. Lipitor’s IP defense bought eight months via pediatric exclusivity. Neither stopped the eventual collapse. The strategic goal is to use the bought time to transition revenue to next-generation products or new protected indications before the cliff arrives.<\/p>\n\n\n\n

Tools like DrugPatentWatch make competitive intelligence accessible.<\/strong> The ability to track Paragraph IV certifications, PTAB petitions, ANDA approvals, and competitor patent expirations in real time changes the speed at which IP teams can respond to competitive signals. Companies that use these tools systematically are operating with better information than those that rely on periodic manual review.<\/p>\n\n\n\n

The Inflation Reduction Act adds a new clock.<\/strong> Medicare negotiation eligibility\u2014triggered at nine years post-approval for small molecules and thirteen years for biologics without generic competition\u2014creates a revenue compression event that operates independently of the patent system. IRA negotiation exposure must be incorporated into revenue modeling alongside patent expiration analysis.<\/p>\n\n\n\n

Financial modeling should connect directly to IP analysis.<\/strong> The value of each patent layer is measurable: it is the present value of revenues that layer protects, multiplied by the probability of patent survival. This calculation should drive resource allocation for patent defense, LCM investment, and BD strategy. IP teams that can speak this language will have far more influence over capital allocation decisions.<\/p>\n\n\n\n

\n\n\n\n

Frequently Asked Questions<\/h2>\n\n\n\n

Q1: What is the single most important thing to do when a Paragraph IV certification arrives for one of your patents?<\/strong><\/p>\n\n\n\n

Act within 45 days. The 30-month stay that blocks FDA from approving the generic ANDA is triggered only if the patent owner or NDA holder files suit within 45 days of receiving the certification notice. Missing that deadline forfeits the automatic stay entirely\u2014meaning FDA can approve the ANDA even while litigation is pending. As soon as a Paragraph IV notice is received, patent counsel should be engaged immediately to evaluate the strength of the infringement and validity positions. If the decision is made not to sue, that should be a deliberate strategic choice rather than a default outcome of missing a deadline.<\/p>\n\n\n\n

Q2: How do biosimilar patent disputes differ mechanically from small-molecule Hatch-Waxman disputes?<\/strong><\/p>\n\n\n\n

The Biologics Price Competition and Innovation Act operates through a “patent dance”\u2014a structured information exchange between the reference product sponsor (originator) and biosimilar applicant. The biosimilar applicant shares its manufacturing information and proposed product description; the originator identifies patents it believes would be infringed; the parties negotiate which patents to litigate in the first wave and which to defer. This process is more collaborative on the front end than Hatch-Waxman\u2014but it can also be used strategically by either side to sequence litigation advantageously. The BPCIA patent dance has been extensively litigated (including in Amgen v. Sandoz, decided by the Supreme Court in 2017), and its procedural requirements are now better defined, if still complex [15].<\/p>\n\n\n\n

Q3: Is it possible to add patents to the Orange Book after a drug is approved, and what constraints apply?<\/strong><\/p>\n\n\n\n

Yes. The Orange Book listing obligation is ongoing: NDA holders must list patents that claim the drug or method of use within 30 days of patent issuance if the patent would be eligible for listing. Patents filed and issued after the original NDA approval are listable if they meet the substantive criteria. The FTC has recently challenged certain post-approval Orange Book listings\u2014particularly for inhaler devices and drug-device combinations\u2014arguing that device patents that do not specifically claim the approved drug product should not be listed. FDA’s own position on the scope of listable patents has evolved, and the agency has issued guidance on the subject [16]. The takeaway is that late-filed patents can be listed, but each listing decision should be made with legal counsel who is current on FTC enforcement posture and recent FDA guidance.<\/p>\n\n\n\n

Q4: How does a company evaluate whether to pursue a “product hop” versus simply defending the existing product?<\/strong><\/p>\n\n\n\n

The central question is whether the new product offers clinically meaningful advantages that physicians and patients actually value\u2014not just the company’s promotional assertion that they do. A product hop supported by real clinical data (reduced side effects, better adherence, improved outcomes in a specific population) is much more defensible commercially and legally than one that is identical in all meaningful respects to the original. Commercially, the migration depends on managed care cooperation: if payers refuse to give the new product preferred formulary status and continue covering the generic alternative, the hop fails regardless of promotional effort. Legally, discontinuing the original product to force migration is the highest-risk variant; voluntary migration through clinical pull is far safer. Before committing to a product hop strategy, model the migration rate under realistic payer and prescriber adoption assumptions\u2014not best-case promotional scenarios.<\/p>\n\n\n\n

Q5: What does the Inflation Reduction Act’s drug price negotiation regime actually mean for IP strategy going forward?<\/strong><\/p>\n\n\n\n

The IRA’s negotiation program applies to drugs that Medicare Part D or Part B spends the most on and that lack generic or biosimilar competition after nine years (small molecules) or thirteen years (biologics) from initial approval. The program effectively caps the upside from a successful patent thicket\u2014if your drug generates high Medicare spending and has kept competition at bay for the required period, it becomes a negotiation target regardless of how many patents remain in force. This does not invalidate the patent thicket strategy; it means the financial model for a drug’s protected revenue period should reflect the likely Medicare price reduction that negotiation would impose in the relevant years. For drugs with very high Medicare exposure, the effective financial value of patent protection beyond nine or thirteen years may be lower than the nominal revenue at risk suggests, because the negotiated price will reduce the revenue per unit even while exclusivity is maintained. IRA negotiation targets should be identified early and incorporated into LCM planning, since the best response may be to accelerate revenue recognition before negotiation eligibility triggers rather than to maximize the protected period at declining prices.<\/p>\n\n\n\n

\n\n\n\n

References<\/h2>\n\n\n\n

[1] Pfizer Inc. (2011, 2012, 2013). Annual Report on Form 10-K<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=PFE&type=10-K<\/p>\n\n\n\n

[2] AbbVie Inc. (2023). Annual Report on Form 10-K<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=ABBV&type=10-K<\/p>\n\n\n\n

[3] GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021), modified on reh’g en banc, 25 F.4th 943 (Fed. Cir. 2022).<\/p>\n\n\n\n

[4] Dafny, L., & Ody, C. (2023). The FDA’s biosimilar policies and Humira competition. Health Affairs<\/em>, 42(4), 524\u2013532. https:\/\/doi.org\/10.1377\/hlthaff.2022.01271<\/p>\n\n\n\n

[5] AstraZeneca PLC. (2011\u20132016). Annual Reports and Form 20-F<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/cgi-bin\/browse-edgar?action=getcompany&CIK=AZN&type=20-F<\/p>\n\n\n\n

[6] U.S. Patent and Trademark Office. (2024). Patent Trial and Appeal Board Statistics: FY2024 Q4<\/em>. USPTO. https:\/\/www.uspto.gov\/patents\/ptab\/statistics<\/p>\n\n\n\n

[7] KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).<\/p>\n\n\n\n

[8] Amgen Inc. v. Sanofi, 598 U.S. 594 (2023).<\/p>\n\n\n\n

[9] Federal Trade Commission. (2011). Authorized Generic Drugs: Short-Term Effects and Long-Term Impact<\/em>. FTC. https:\/\/www.ftc.gov\/sites\/default\/files\/documents\/reports\/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission\/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf<\/p>\n\n\n\n

[10] FTC v. Actavis, Inc., 570 U.S. 136 (2013).<\/p>\n\n\n\n

[11] Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, 121 Stat. 823 (2007).<\/p>\n\n\n\n

[12] New York v. Actavis PLC, No. 14 Civ. 7473 (S.D.N.Y. Sept. 5, 2014) (preliminary injunction order).<\/p>\n\n\n\n

[13] Kanavos, P., & Costa-Font, J. (2005). Pharmaceutical parallel trade in Europe: Stakeholder and competition effects. Economic Policy<\/em>, 20(44), 751\u2013798. https:\/\/doi.org\/10.1111\/j.1468-0327.2005.00150.x<\/p>\n\n\n\n

[14] Inflation Reduction Act of 2022, Pub. L. No. 117-169, 136 Stat. 1818 (2022).<\/p>\n\n\n\n

[15] Amgen Inc. v. Sandoz Inc., 582 U.S. 1 (2017).<\/p>\n\n\n\n

[16] U.S. Food and Drug Administration. (2023). Listing of Patent Information in the Orange Book: Guidance for Industry<\/em>. FDA. https:\/\/www.fda.gov\/media\/168891\/download<\/p>\n","protected":false},"excerpt":{"rendered":"

The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is […]<\/p>\n","protected":false},"author":1,"featured_media":36823,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-36333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=36333"}],"version-history":[{"count":2,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36333\/revisions"}],"predecessor-version":[{"id":36824,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/36333\/revisions\/36824"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/36823"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=36333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=36333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=36333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}